Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Subasumstat |
| Synonyms | |
| Therapy Description |
Subasumstat (TAK-981) is a small molecule inhibitor of the SUMO-activating enzyme (SAE), which may lead to activation of anti-tumor immune response and inhibition of tumor growth (PMID: 37420267). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Subasumstat | TAK981|TAK 981|TAK-981 | Subasumstat (TAK-981) is a small molecule inhibitor of the SUMO-activating enzyme (SAE), which may lead to activation of anti-tumor immune response and inhibition of tumor growth (PMID: 37420267). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04065555 | Phase I | Avelumab + Subasumstat Cetuximab Cetuximab + Subasumstat Subasumstat Avelumab | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Completed | USA | 0 |
| NCT03648372 | Phase I | Subasumstat | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |